Crossmark

Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018

Crossref DOI link: https://doi.org/10.1007/s12325-022-02173-7

Published Online: 2022-06-23

Published Print: 2022-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Yifei https://orcid.org/0000-0003-3597-8706
Skup, Martha

Yang, Min

Qi, Cynthia Z.

Wu, Eric Q.
Funding

Funding for this research was provided by:

AbbVie
License Information

Text and Data Mining valid from 2022-06-23

Version of Record valid from 2022-06-23
More Information

Article History

Received: 15 February 2022

Accepted: 26 April 2022

First Online: 23 June 2022

Change Date: 30 August 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s12325-022-02255-6

Updates are available Correction dated 2022-08-30

Click to view Correction: https://doi.org/10.1007/s12325-022-02255-6